Dr. Bret E. Friday
Claim this profileEssentia Health Cancer Center
Expert in Parotid Gland Cancer
Expert in Cancer
125 reported clinical trials
200 drugs studied
About Bret E. Friday
Education:
- Graduated with an MD from the University of Minnesota Medical School, Twin Cities Campus, in 2007.
- Completed Residency in Radiation Oncology at the University of Minnesota Medical Center in 2012.
- Undertook a Fellowship in Brachytherapy at the University of Minnesota Medical Center in 2013.
Experience:
- Board Certified in Radiation Oncology by the American Board of Radiology.
- Has been practicing as a Radiation Oncologist at Essentia Health Cancer Center since 2013.
Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage I
2Cancer
Global LeaderStage IV
KRAS positive
Stage III
Affiliated Hospitals
Clinical Trials Bret E. Friday is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
More about Bret E. Friday
Clinical Trial Related6 years of experience running clinical trials · Led 125 trials as a Principal Investigator · 62 Active Clinical TrialsTreatments Bret E. Friday has experience with
- Nivolumab
- Pembrolizumab
- Paclitaxel
- Carboplatin
- Fluorouracil
- Ipilimumab
Breakdown of trials Bret E. Friday has run
Parotid Gland Cancer
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cervical Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Bret E. Friday specialize in?
Is Bret E. Friday currently recruiting for clinical trials?
Are there any treatments that Bret E. Friday has studied deeply?
What is the best way to schedule an appointment with Bret E. Friday?
What is the office address of Bret E. Friday?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.